Using AI to predict chemotherapy side effects in cancer patients
Developing Artificial Intelligence-based Algorism Based on Life-log Data Acquired From Wearable Device for the Prediction of Chemotherapy-induced Side Effects and Symptom
This study is testing whether an AI tool can help predict side effects from chemotherapy for people with lung, head and neck, and esophageal cancers to improve their treatment experience.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul, Gangnamgu) |
| Trial ID | NCT05937477 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop an artificial intelligence-based algorithm to predict side effects from chemotherapy in patients with lung, head and neck, and esophageal cancers. Participants will wear a device to collect disease-based biomarkers and report their adverse events through a mobile app. The study will analyze the relationship between these biomarkers, patient quality of life, and chemotherapy outcomes, including completion rates and emergency room visits. Blood samples will also be collected for pharmacogenomics testing to further understand side effects associated with chemotherapy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 20 and older diagnosed with lung, head and neck, or esophageal cancer who are scheduled to receive chemotherapy.
Not a fit: Patients who have difficulty using the mobile app or are deemed unable to participate by medical staff may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of chemotherapy side effects, enhancing patient quality of life and treatment adherence.
How similar studies have performed: While the use of AI in predicting chemotherapy side effects is an emerging field, similar studies have shown promise in utilizing technology for patient monitoring and outcome prediction.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 20 years of age or older * Must have diagnosed with lung, head and neck, or esophageal cancer, 1. scheduled to receive their first treatment in preoperative or postoperative chemotherapy. 2. scheduled for systemic chemotherapy due to recurrence or metastasis. * Eastern Cooperative Oncology (ECOG) performance status of 0 to 2. * Patients who have access to a smartphone and can use the mobile app on their own. * Understand the purpose of the study and agree to participate in the study. Exclusion Criteria: * Patients who, in the judgment of the researcher, have difficulty using the application. * Patients who are judged by the medical staff to be unable to participate in the study.
Where this trial is running
Seoul, Gangnamgu
- Samsung Medical Center — Seoul, Gangnamgu, South Korea (Recruiting)
Study contacts
- Study coordinator: Sehhoon Park, MD
- Email: sehhoon.park@samsung.com
- Phone: +82-10-9185-8619
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.